Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Study of Hsp90 Inhibitor, STA-9090 for Relapsed or Refractory Small Cell Lung Cancer

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified February 2013 by Dana-Farber Cancer Institute.
Recruitment status was:  Active, not recruiting
Massachusetts General Hospital
Beth Israel Deaconess Medical Center
Synta Pharmaceuticals Corp.
Information provided by (Responsible Party):
Leena Gandhi, MD, PhD, Dana-Farber Cancer Institute Identifier:
First received: July 29, 2010
Last updated: February 22, 2013
Last verified: February 2013
No Study Results Posted on for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: August 2013 (Final data collection date for primary outcome measure)